ACTRN12621000924853招募中未知
Safety, efficacy and tolerability of the Novoglan foreskin tissue expander product as a conservative treatment for adult phimosis.
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit(—)
- 性别
- Male
入选标准
- •The Novoglan-01 study inclusion criteria are as follows.
- •1.Male 18 or older referred to the urology clinic
- •2.Symptoms of adult phimosis with inability to fully retract the foreskin
- •3.Reporting of pain or discomfort
- •4.Potential participant may have Balanitis Xerotica Obliterans or undergone prior frenuloplasty
- •5.Willingness to provide informed consent and willingness to participate and comply with the study requirements.
排除标准
- •The Novoglan-01 study exclusion criteria are as follows.
- •1.Any known allergy to latex or silicones
- •2.Any bleeding, ulcer or active infection of the penis
- •3.Any prior prepuce surgery, except for frenuloplasty
- •4.Any hypospadia
- •5.Any severe scaring of the glans or foreskin
- •6.Any history of penile cancer
- •7.Participants with a history of a psychological illness or other conditions which may interfere with their ability to understand the study requirements
研究者
相似试验
招募中
2 期
Gallecina(R) capsule in COVID-19IRCT20180103038199N12Mashhad University of Medical Sciences140
尚未招募
Unknown
To know if the mouth wash prepared from certain herbal products is effective and safe to treat the gingivitisCTRI/2024/01/061413DR ZADC AMU ALIGARH
已完成
不适用
The efficacy and the safety of the new long-acting insulin in patient with diabetesdiabetesJPRN-UMIN000020521Osaka Saiseikai Noe Hospital100
招募中
3 期
A clinical study to evaluate the efficacy and safety of the Vamana karma followed with two Rasayanas Takradhara and Rasaoushadi in treatment of psoriasis.CTRI/2016/02/006631Central council for Research in Ayurvedic sciences CCRAS110
招募中
1 期
Effect of NK cell therapy in COVID-19IRCT20200417047113N1Middle East Gene Therapy corporation70
